Incanthera PLC Directorate Change (4914C)
23 Febbraio 2022 - 8:01AM
UK Regulatory
TIDMINC
RNS Number : 4914C
Incanthera PLC
23 February 2022
23 February 2022
Incanthera plc
("Incanthera" or the "Company")
Directorate Changes
Incanthera plc (AQSE: INC), the specialist company focused on
innovative technologies in oncology and dermatology, is pleased to
announce the appointment of Caroline Murray as a Non-executive
Director with immediate effect.
Caroline brings extensive product management and marketing
experience to the Board, having held senior positions in both
Novartis and Bristol Myers Squibb ("BMS"). The Board believes
Caroline's experience and skillset is perfectly suited to the
company's near-term goals and ambitions as we look to commercialise
our lead product Sol.
Dr. Alan Warrander has advised the Board of his intention to
retire to concentrate on his family and leisure interests. This
will take effect on 28 February 2022.
Alan joined the team in 2012 as a consultant advising on
partnering and licensing and was appointed a Non-executive Director
that year, drawing on over 30 years' experience within global
pharma drug discovery and drug development processes, including 21
years with AstraZeneca.
Commenting on the Board changes announced today, Chairman, Tim
McCarthy, said:
"W e are delighted to announce the appointment of Caroline as a
Non-executive Director. Caroline's experience in product management
and marketing demonstrates exactly the skillset that will
strengthen the Board as we progress towards the commercialisation
of our lead product Sol. We warmly welcome Caroline to the
Incanthera team."
Alan has been integral in Incanthera's path to date. With his
outstanding industry experience and his sound and wise counsel to
the Board, we all owe a great debt to Alan's contribution. Alan
will be very much missed by the whole of the Incanthera team. We
thank him and wish him a long and happy retirement as he now
concentrates on his family and leisure pursuits."
The following information relating to Caroline Murray is
disclosed pursuant to Rule 4.9 of the AQSE Growth Market - Access
Rulebook:
Caroline Diana Murray (aged 51) is a director of CDM Consulting
(UK) Ltd and has not held any other directorships in the last five
years. Caroline Murray does not hold any shares in the Company.
There is no further information to be disclosed pursuant to Rule
4.9 of the AQSE Growth Market Rulebook.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014 (which forms part of
domestic UK law pursuant to the European Union (Withdrawal) Act
2018).
The directors of the Company take responsibility for this
announcement.
For further enquiries:
Incanthera plc
www.incanthera.com
Tim McCarthy, Chairman
tim.mccarthy@incanthera.com +44 (0) 7831 675747
Simon Ward, Chief Executive Officer
simon.ward@incanthera.com +44 (0) 7747 625506
Suzanne Brocks, Head of Communications
suzanne.brocks@incanthera.com +44 (0) 7776 234600
Aquis Exchange Corporate Adviser:
Cairn Financial Advisers LLP
Jo Turner/James Lewis +44 (0) 20 7213 0880
Broker
Stanford Capital Partners Ltd
Patrick Claridge/John Howes/Bob Pountney + 44 (0) 203 650 3650
Notes to Editors
Incanthera is a specialist oncology company focused on
innovative technologies in oncology and dermatology. It seeks to
identify and develop innovative solutions to current clinical,
commercially relevant unmet needs, utilising new technology from
leading academic institutions.
The Company's current lead product and focus is Sol, a
potentially innovative topical product for the treatment of solar
keratosis and the prevention of skin cancers. This has achieved
proof of concept and the Company is now focussed upon delivering
Sol to a commercial partner.
The Company originated from the Institute of Cancer Therapeutics
("ICT") at the University of Bradford and has acquired and
developed a portfolio of specific cancer-targeting therapeutics
through a Pipeline Agreement with the ICT and other corporate
acquisitions.
Incanthera's strategy is to develop each candidate in the
portfolio from initial acquisition or discovery to securing its
future through commercially valuable partnerships at the earliest
opportunity in its development pathway.
For more information on the Company please visit:
www.incanthera.com
@incantheraplc
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXSEWEEEEESEEE
(END) Dow Jones Newswires
February 23, 2022 02:01 ET (07:01 GMT)
Grafico Azioni Incanthera (AQSE:INC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Incanthera (AQSE:INC)
Storico
Da Apr 2023 a Apr 2024